Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

L.S. Schneider; R.E. Kennedy; G.R. Cutter; N.C. Fox

doi:10.1016/j.jalz.2010.07.004

Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

L.S. Schneider, R.E. Kennedy, G.R. Cutter, N.C. Fox

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	367-377
Journal	Alzheimers & Dementia
Volume	6
Issue number	5
DOIs	https://doi.org/10.1016/j.jalz.2010.07.004
Publication status	Published - 2010

Access to Document

10.1016/j.jalz.2010.07.004

Cite this

@article{498507b54c244b17be9aa136d4c3aeaf,

title = "Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials",

author = "L.S. Schneider and R.E. Kennedy and G.R. Cutter and N.C. Fox",

year = "2010",

doi = "10.1016/j.jalz.2010.07.004",

language = "Undefined/Unknown",

volume = "6",

pages = "367--377",

journal = "Alzheimers & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

AU - Schneider, L.S.

AU - Kennedy, R.E.

AU - Cutter, G.R.

AU - Fox, N.C.

PY - 2010

Y1 - 2010

U2 - 10.1016/j.jalz.2010.07.004

DO - 10.1016/j.jalz.2010.07.004

M3 - Article

C2 - 20813339

VL - 6

SP - 367

EP - 377

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

IS - 5

ER -